We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-1.21%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.35B
AUM Growth
+$59.1M
(+4.6%)
Cap. Flow
+$135M
Cap. Flow
% of AUM
9.97%
Top 10 Holdings %
Top 10 Hldgs %
58.23%
Holding
42
New
1
Increased
8
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield
BN
|
+$110M |
| 2 |
Brookfield Asset Management
BAM
|
+$21.2M |
| 3 |
Cable One
CABO
|
+$16M |
| 4 |
Inspire Medical Systems
INSP
|
+$6.94M |
| 5 |
IOBT
IO Biotech
IOBT
|
+$4.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VERV
Verve Therapeutics
VERV
|
+$9.38M |
| 2 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$8.23M |
| 3 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
+$6.55M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.75M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$5.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.32% |
| 2 | Technology | 24.11% |
| 3 | Financials | 10.51% |
| 4 | Industrials | 5.46% |
| 5 | Communication Services | 5.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Brookfield
BN
$102B
| $121M | 8.97% |
5,820,345
+4,879,534
| +519% | +$110M |
|
2
ASML
ASML
$596B
| $116M | 8.6% |
197,760
| – | – |
|
3
Salesforce
CRM
$154B
| $108M | 7.95% |
530,500
| – | – |
|
4
Corcept Therapeutics
CORT
$9.98B
| $92M | 6.8% |
3,377,768
| – | – |
|
5
LanzaTech
LNZA
$59.9M
| $73.9M | 5.46% |
158,148
| – | – |
|
|
6
Cable One
CABO
$237M
| $72.9M | 5.39% |
118,403
+24,300
| +26% | +$16M |
|
7
TSMC
TSM
$1.94T
| $61.8M | 4.56% |
710,780
| – | – |
|
8
Disc Medicine
IRON
$2.81B
| $51.2M | 3.79% |
1,090,772
| – | – |
|
|
9
Mirum Pharmaceuticals
MIRM
$6.56B
| $47.4M | 3.5% |
1,500,000
-184,193
| -11% | -$5.04M |
|
10
Alibaba
BABA
$276B
| $43.4M | 3.21% |
500,827
| – | – |
|
11
Vaxcyte
PCVX
$7.65B
| $43.1M | 3.18% |
845,000
| – | – |
|
|
ACLX
12
DELISTED
Arcellx
ACLX
| $38.6M | 2.85% |
1,075,000
+75,000
| +8% | +$2.59M |
|
13
Apple
AAPL
$4.97T
| $37.9M | 2.8% |
221,460
| – | – |
|
14
BioMarin Pharmaceuticals
BMRN
$11.9B
| $35.4M | 2.62% |
400,000
| – | – |
|
15
Edgewise Therapeutics
EWTX
$4.28B
| $34.8M | 2.57% |
6,071,703
| – | – |
|
|
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
| $33.9M | 2.51% |
159,986
| – | – |
|
17
Insmed
INSM
$22.4B
| $33.8M | 2.5% |
1,339,304
| – | – |
|
18
Crinetics Pharmaceuticals
CRNX
$8.88B
| $32.7M | 2.42% |
1,100,000
| – | – |
|
19
Pharvaris
PHVS
$2.28B
| $27.7M | 2.05% |
1,329,325
| – | – |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $26.4M | 1.95% |
525,000
+76,196
| +17% | +$4.07M |
|
|
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
| $25.5M | 1.88% |
2,095,900
| – | – |
|
|
OKUR
22
OnKure Therapeutics
OKUR
$160M
| $25.3M | 1.87% |
333,038
| – | – |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $23.4M | 1.73% |
1,566,521
-433,479
| -22% | -$5.75M |
|
24
Alnylam Pharmaceuticals
ALNY
$38.3B
| $21M | 1.55% |
118,383
| – | – |
|
|
25
Brookfield Asset Management
BAM
$75.6B
| $20.9M | 1.55% |
+627,207
| New | +$21.2M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q3 2023 Portfolio in Review
As of Q3 2023, Novo Holdings A/S held 42 positions worth $1.35B, up 4.6% from $1.29B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Novo Holdings A/S deployed $135M of net new capital in Q3 2023, opening 1 new position and adding to 8 existing holdings. Its largest new stake was Brookfield Asset Management: 627,207 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 53% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Cyteir Therapeutics, Inc. Common Stock, an estimated $8.23M trimmed.
- Novo Holdings A/S's largest Q3 2023 buy was Brookfield Asset Management: 627,207 shares worth $20.9M.
- Novo Holdings A/S added most to Brookfield in Q3 2023, an estimated $110M increase.
- Novo Holdings A/S's biggest Q3 2023 reduction was Cyteir Therapeutics, Inc. Common Stock, cutting an estimated $8.23M.
- Novo Holdings A/S fully exited Verve Therapeutics in Q3 2023, selling an estimated $9.38M.
- Novo Holdings A/S's ten largest holdings make up 58% of its $1.35B portfolio in Q3 2023.
- Novo Holdings A/S opened 1 new position and closed 2 in Q3 2023.
- Novo Holdings A/S's portfolio value rose 4.6% quarter-over-quarter to $1.35B.
Based on Novo Holdings A/S's 13F filing for Q3 2023, filed 14 Nov 2023.